Published in Cancer Biol Ther on October 01, 2010
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Pancreatic cancer. Lancet (2004) 11.63
MuSiC: identifying mutational significance in cancer genomes. Genome Res (2012) 4.73
Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res (2012) 2.27
Protein kinase signaling networks in cancer. Curr Opin Genet Dev (2010) 1.41
The MPS1 family of protein kinases. Annu Rev Biochem (2012) 1.38
NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway. J Cell Biol (2011) 1.34
Improving the prediction of the functional impact of cancer mutations by baseline tolerance transformation. Genome Med (2012) 1.32
CHASM and SNVBox: toolkit for detecting biologically important single nucleotide mutations in cancer. Bioinformatics (2011) 1.18
Sequence analysis of 515 kinase genes in chronic lymphocytic leukemia. Leukemia (2011) 1.18
Molecular characteristics of pancreatic ductal adenocarcinoma. Patholog Res Int (2011) 1.03
High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. J Med Genet (2014) 1.01
The Nek8 protein kinase, mutated in the human cystic kidney disease nephronophthisis, is both activated and degraded during ciliogenesis. Hum Mol Genet (2011) 0.99
Downregulation of the CCK-B receptor in pancreatic cancer cells blocks proliferation and promotes apoptosis. Am J Physiol Gastrointest Liver Physiol (2012) 0.92
Integrated analysis of recurrent properties of cancer genes to identify novel drivers. Genome Biol (2013) 0.91
A graph theoretic approach to utilizing protein structure to identify non-random somatic mutations. BMC Bioinformatics (2014) 0.91
Driver mutations: a roadmap for getting close and personal in pancreatic cancer. Cancer Biol Ther (2010) 0.85
A single nucleotide polymorphism of the cholecystokinin-B receptor predicts risk for pancreatic cancer. Cancer Biol Ther (2012) 0.85
Protein-structure-guided discovery of functional mutations across 19 cancer types. Nat Genet (2016) 0.84
Genomic landscape of endometrial stromal sarcoma of uterus. Oncotarget (2015) 0.82
Diacylglycerol kinase α promotes 3D cancer cell growth and limits drug sensitivity through functional interaction with Src. Oncotarget (2014) 0.80
Functional annotation of putative regulatory elements at cancer susceptibility Loci. Cancer Inform (2014) 0.79
Concurrent Mutations in ATM and Genes Associated with Common γ Chain Signaling in Peripheral T Cell Lymphoma. PLoS One (2015) 0.78
Mutational burdens and evolutionary ages of thyroid follicular adenoma are comparable to those of follicular carcinoma. Oncotarget (2016) 0.78
iCAGES: integrated CAncer GEnome Score for comprehensively prioritizing driver genes in personal cancer genomes. Genome Med (2016) 0.77
Reverse engineering biomolecular systems using -omic data: challenges, progress and opportunities. Brief Bioinform (2012) 0.77
Progression of naive intraepithelial neoplasia genome to aggressive squamous cell carcinoma genome of uterine cervix. Oncotarget (2015) 0.76
A Survey of Computational Tools to Analyze and Interpret Whole Exome Sequencing Data. Int J Genomics (2016) 0.75
NEK8 regulates DNA damage-induced RAD51 foci formation and replication fork protection. Cell Cycle (2016) 0.75
Whole-exome sequencing identified mutational profiles of high-grade colon adenomas. Oncotarget (2017) 0.75
The serine/threonine kinase 33 is present and expressed in palaeognath birds but has become a unitary pseudogene in neognaths about 100 million years ago. BMC Genomics (2015) 0.75
Modulated DISP3/PTCHD2 expression influences neural stem cell fate decisions. Sci Rep (2017) 0.75
Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts. Front Physiol (2014) 0.75
STK33 potentiates the malignancy of hypopharyngeal squamous carcinoma: Possible relation to calcium. Cancer Biol Ther (2016) 0.75
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
The Universal Protein Resource (UniProt): an expanding universe of protein information. Nucleic Acids Res (2006) 22.70
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell (2006) 10.06
Pancreatic cancer. Annu Rev Pathol (2008) 6.96
The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol (2010) 6.91
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell (2000) 5.23
COSMIC 2005. Br J Cancer (2006) 5.07
Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res (2009) 4.92
PI(3)Kgamma has an important context-dependent role in neutrophil chemokinesis. Nat Cell Biol (2006) 3.12
Pancreatic cancer and precursor pancreatic intraepithelial neoplasia lesions are devoid of primary cilia. Cancer Res (2009) 2.43
NEK8 mutations affect ciliary and centrosomal localization and may cause nephronophthisis. J Am Soc Nephrol (2008) 2.39
A defect in a novel Nek-family kinase causes cystic kidney disease in the mouse and in zebrafish. Development (2002) 2.00
Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kgamma. Nature (2000) 1.93
Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. J Am Soc Nephrol (2006) 1.78
Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms' tumor. PLoS Genet (2009) 1.77
Nek8 regulates the expression and localization of polycystin-1 and polycystin-2. J Am Soc Nephrol (2008) 1.70
Stonin 2: an adaptor-like protein that interacts with components of the endocytic machinery. J Cell Biol (2001) 1.63
Nek8, a NIMA family kinase member, is overexpressed in primary human breast tumors. Gene (2004) 1.52
Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res (2007) 1.52
B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells. Oncogene (2007) 1.38
Primary cilia and the cell cycle. Methods Cell Biol (2009) 1.28
The multiple roles of phosphoinositide 3-kinase in mast cell biology. Trends Immunol (2008) 1.27
Inactivation of PI3Kgamma and PI3Kdelta distorts T-cell development and causes multiple organ inflammation. Blood (2007) 1.27
Inner ear localization of mRNA and protein products of COCH, mutated in the sensorineural deafness and vestibular disorder, DFNA9. Hum Mol Genet (2001) 1.25
PRDM5 is silenced in human cancers and has growth suppressive activities. Oncogene (2004) 1.24
PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer. Clin Cancer Res (2007) 1.21
Epigenetic regulation of protein-coding and microRNA genes by the Gfi1-interacting tumor suppressor PRDM5. Mol Cell Biol (2007) 1.19
Activation of protein kinase C subtypes alpha, gamma, delta, epsilon, zeta, and eta by tumor-promoting and nontumor-promoting agents. Biochem Pharmacol (1997) 1.09
Form and flexibility in phosphoinositide 3-kinases. Biochem Soc Trans (2009) 1.08
Expression of calbindin-D(28k) in a pancreatic islet beta-cell line protects against cytokine-induced apoptosis and necrosis. Endocrinology (2001) 1.05
Down-regulation of PIK3CG, a catalytic subunit of phosphatidylinositol 3-OH kinase, by CpG hypermethylation in human colorectal carcinoma. Clin Cancer Res (2002) 1.04
Activation of diacylglycerol kinase alpha is required for VEGF-induced angiogenic signaling in vitro. Oncogene (2004) 1.03
PKC gamma mutations in spinocerebellar ataxia type 14 affect C1 domain accessibility and kinase activity leading to aberrant MAPK signaling. J Cell Sci (2008) 1.03
A syngeneic variance library for functional annotation of human variation: application to BRCA2. Cancer Res (2008) 1.02
Diacylglycerol kinase alpha suppresses tumor necrosis factor-alpha-induced apoptosis of human melanoma cells through NF-kappaB activation. Biochim Biophys Acta (2007) 1.01
Activation of alpha-diacylglycerol kinase is critical for the mitogenic properties of anaplastic lymphoma kinase. Blood (2005) 1.00
Genomic structure of the PIK3CG gene on chromosome band 7q22 and evaluation as a candidate myeloid tumor suppressor. Blood (2002) 1.00
Consequences of the expression of sialylated antigens in breast cancer. Carbohydr Res (2010) 0.97
Differential expression pattern of the novel serine/threonine kinase, STK33, in mice and men. FEBS J (2005) 0.94
TTK/Mps1 controls nuclear targeting of c-Abl by 14-3-3-coupled phosphorylation in response to oxidative stress. Oncogene (2008) 0.94
The p110gamma isoform of phosphatidylinositol 3-kinase regulates migration of effector CD4 T lymphocytes into peripheral inflammatory sites. J Leukoc Biol (2008) 0.93
Mitotic checkpoint genes hBUB1, hBUB1B, hBUB3 and TTK in human bladder cancer, screening for mutations and loss of heterozygosity. Carcinogenesis (2001) 0.93
Nuclear localization signal of murine CMP-Neu5Ac synthetase includes residues required for both nuclear targeting and enzymatic activity. J Biol Chem (2002) 0.89
Signaling at the membrane interface by the DGK/SK enzyme family. J Lipid Res (2008) 0.82
Finding the weakness in cancer. N Engl J Med (2009) 0.80
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell (2005) 14.21
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature (2011) 9.70
Pancreatic cancer. Lancet (2011) 8.54
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg (2006) 7.18
Pancreatic cancer. Annu Rev Pathol (2008) 6.96
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol (2009) 6.43
An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res (2006) 5.52
Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell (2003) 5.36
Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg (2004) 5.12
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res (2009) 4.92
Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol (2008) 4.70
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci U S A (2010) 4.47
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol (2006) 4.22
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63
MODBASE: a database of annotated comparative protein structure models and associated resources. Nucleic Acids Res (2006) 3.56
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51
Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol (2008) 3.51
Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science (2011) 3.49
Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery (2007) 3.42
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol (2003) 3.40
Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med (2004) 3.39
Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res (2004) 3.31
ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov (2011) 3.27
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature (2012) 3.23
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res (2003) 3.23
Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol (2008) 3.14
Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol (2004) 3.10
Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol (2006) 3.01
A compendium of potential biomarkers of pancreatic cancer. PLoS Med (2009) 3.00
Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. Hepatology (2014) 2.98
Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet (2013) 2.91
Recent progress in pancreatic cancer. CA Cancer J Clin (2013) 2.88
Acinar cells contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia. Am J Pathol (2007) 2.87
Focus on pancreas cancer. Cancer Cell (2002) 2.82
Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch (2005) 2.76
Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology (2012) 2.74
MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res (2013) 2.71
LigAmp for sensitive detection of single-nucleotide differences. Nat Methods (2004) 2.70
Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology (2012) 2.69
Combining local-structure, fold-recognition, and new fold methods for protein structure prediction. Proteins (2003) 2.67
Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics (2005) 2.66
Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res (2005) 2.64
Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol (2003) 2.63
Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res (2003) 2.49
P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci U S A (2010) 2.49
Precursors to invasive pancreatic cancer. Adv Anat Pathol (2005) 2.45
PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol (2007) 2.45
SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res (2009) 2.44
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell (2007) 2.36
Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res (2003) 2.35
Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol (2002) 2.35
Direct correlation between proliferative activity and dysplasia in pancreatic intraepithelial neoplasia (PanIN): additional evidence for a recently proposed model of progression. Mod Pathol (2002) 2.33
SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene (2003) 2.32
Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci Transl Med (2013) 2.30
Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res (2012) 2.27
Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res (2002) 2.23
Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol (2002) 2.22
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther (2010) 2.21
Pancreaticoduodenectomy (Whipple resections) in patients without malignancy: are they all 'chronic pancreatitis'? Am J Surg Pathol (2003) 2.20
MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol (2002) 2.18
Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut (2012) 2.17
miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. Clin Cancer Res (2012) 2.10
Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. Cancer Biol Ther (2008) 2.09
Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery (2006) 2.07
Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res (2002) 2.07
PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res (2007) 2.06
Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomarkers Prev (2006) 2.04
Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion. Mod Pathol (2005) 2.03
The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2007) 2.03
Discriminative prediction of mammalian enhancers from DNA sequence. Genome Res (2011) 2.02
MODBASE, a database of annotated comparative protein structure models and associated resources. Nucleic Acids Res (2008) 2.02
Impact of the time interval between MDCT imaging and surgery on the accuracy of identifying metastatic disease in patients with pancreatic cancer. AJR Am J Roentgenol (2015) 2.00
Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol (2012) 1.99
MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res (2011) 1.97
Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol (2002) 1.96